Practical perspective on the decisions clinicians face in the clinic: how to sequence therapy, deliver it safely, and widen access.
CAR T-cell therapy versus bispecifics and how to choose, especially at early relapse and after BCMA-directed therapy.
Delivering advanced therapies safely in real-world settings, dosing, monitoring, and toxicity management.
Extending specialized care beyond major academic centers so more patients can benefit.
Short, practical videos for trainees and clinicians on giving CAR T-cell therapy and bispecific antibodies safely.
Recognition, grading, and management of CRS and ICANS with immune effector cell therapies. Watch ↗
Efficacy, safety, and bringing care closer to home, available and emerging bispecific antibodies. Watch ↗
Practical guidance for delivering bispecific antibody therapy safely outside academic centers. Watch ↗
Bringing BCMA-directed bispecifics into newly diagnosed multiple myeloma. Watch ↗
Key trial data, use in high-risk disease, CAR T-cell therapy bridging, and side-effect management. Watch ↗
Real-world outcomes and insights on sequential treatment with BCMA-directed therapies. Watch ↗